Showing results (71-80 of 88) with videos related to
Sort By:
Pageof 9
Sports Medicine and Health Science|May 13, 2026
Evaluating the effectiveness of blood flow restriction training in older adults: An overview of systematic reviewsVictor S de Queiros, Nicholas Rolnick, Jason R Jaggers, et al.Journal of Applied Physiology (Bethesda, Md. : 1985)|November 29, 2024
New insights into the impact of bed rest on lumbopelvic muscles: a computer-vision model approach to measure fat fraction changesEvert O Wesselink, Julie Hides, James M Elliott, et al.British Journal of Cancer|November 23, 2016
Trastuzumab-associated cardiac events in the Persephone trialHelena M Earl, Anne-Laure Vallier, Janet Dunn, et al.Frontiers in Physiology|November 8, 2019
Corrigendum: Blood Flow Restriction Exercise: Considerations of Methodology, Application, and SafetyStephen D Patterson, Luke Hughes, Stuart Warmington, et al.Frontiers in Physiology|June 4, 2019
Blood Flow Restriction Exercise: Considerations of Methodology, Application, and SafetyStephen D Patterson, Luke Hughes, Stuart Warmington, et al.Health Technology Assessment (Winchester, England)|February 12, 2016
OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancerRobert C Stein, Janet A Dunn, John M S Bartlett, et al.Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 16, 2017
Value of Information Analysis of Multiparameter Tests for Chemotherapy in Early Breast Cancer: The OPTIMA Prelim TrialPeter S Hall, Alison Smith, Claire Hulme, et al.The Lancet. Oncology|May 16, 2015
Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trialHelena M Earl, Louise Hiller, Janet A Dunn, et al.The Lancet. Oncology|December 24, 2013
Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trialHelena M Earl, Anne-Laure Vallier, Louise Hiller, et al.Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 27, 2017
Central pathology review with two-stage quality assurance for pathological response after neoadjuvant chemotherapy in the ARTemis TrialJeremy St John Thomas, Elena Provenzano, Louise Hiller, et al.Pageof 9